Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement

Gilead Sciences (GILD) experienced an upward movement in its share price today, accompanied by notable intraday volatility. This positive performance is primarily attributable to significant advancements in the company's product pipeline and regulatory milestones.

The most impactful news contributing to the stock's rise was the U.S. Food and Drug Administration (FDA) approval of Hepcludex (bulevirtide) injection. This marks the first FDA-approved treatment for chronic hepatitis delta virus (HDV infection) in adults without cirrhosis or with compensated cirrhosis, addressing a critical unmet medical need. The efficacy of Hepcludex was demonstrated in a phase 3 trial, showing significant improvement in patients compared to a delayed treatment group.

Further boosting investor confidence, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Trodelvy as a monotherapy. This recommendation is for certain adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have not received prior systemic treatment and are unsuitable for PD-1 or PD-L1 inhibitors. This positive opinion is based on strong results from the Phase III ASCENT-03 study, underscoring the drug's potential in a challenging cancer subtype.

Additionally, upcoming presentations at the 2026 ASCO Annual Meeting and the 2026 EHA Congress are highlighting the momentum in Gilead's oncology programs, including new data analyses for Trodelvy and anitocabtagene autoleucel (anito-cel). This suggests a broadening and strengthening of the company's oncology portfolio. While some reports noted insider selling over the past three months and a lowered Q4 2026 EPS estimate from one research firm, these factors were overshadowed by the significant positive regulatory news and pipeline developments today, which provided a strong catalyst for the stock's upward trajectory.

Technically, Gilead Sciences Inc (GILD) shows a MACD (12,26,9) value of [-1.60], indicating a neutral signal. The RSI at 42.32 suggests neutral condition and the Williams %R at -76.42 suggests oversold condition. Please monitor closely.

Gilead Sciences Inc (GILD) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $29.44B, ranking 15 in the industry. The net profit is $8.51B, ranking 8 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $158.29, a high of $180.00, and a low of $122.00.

Company Specific Risks:

• Gilead Sciences significantly revised its full-year 2026 adjusted earnings guidance to an anticipated loss per share, attributed to an $11.5 billion charge and financing costs related to recent acquisitions of Arcellx, Ouro Medicines, and Tubulis, despite raising revenue forecasts.
• The company issued $3 billion in senior unsecured notes on May 20, 2026, to help fund its acquisition strategy, increasing its financial leverage and future interest obligations.
• The California Supreme Court heard oral arguments on May 6, 2026, in the high-profile "Gilead Tenofovir Cases," where 24,000 HIV patients allege the company intentionally delayed the development of a safer drug to protect profits from an existing one, potentially setting a precedent for product liability and innovation standards.
• Gilead terminated its Phase II/III HIV drug trial (Wonders-2) in April 2026 after the FDA refused to lift a clinical hold due to safety concerns regarding reduced CD4+ T-cell and lymphocyte counts, indicating a setback in pipeline development and execution risk.